Celularity Inc. - Class A Common Stock CELU 深 沪
已收盘 08-01 16:00:00 美东时间
3.12
-0.160
-4.88%
华盛通- 最 高3.30
- 今 开3.30
- 成交量 7.15万股
- 最 低 3.10
- 昨 收 3.28
- 总市值 7472.15万
- 52周最高 5.22
- 市盈率 静 --
- 换手率 0.30%
- 52周最低 1.0007
- 委 比 15.89%
- 总股本 2394.92万
- 历史最高 134.00
- 量 比 0.59
- 振 幅 6.10%
- 历史最低 1.0007
- 每 手 1
- 风险率 0.57%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Celularity Secures $2M Through Private Placement Deal
Celularity ( ($CELU) ) has shared an update. On July 14, 2025, Celularity Inc. ...
07-31 05:21
Celularity Finalizes Private Placement Agreement
Celularity ( ($CELU) ) just unveiled an announcement. On June 23, 2025, Celular...
07-23 05:04
Why Data Storage Shares Are Trading Higher By 35%; Here Are 20 Stocks Moving Premarket
Shares of Data Storage Corporation (NASDAQ:DTST) rose sharply in pre-market tra...
07-16 18:04
Celularity & Fountain Life Announce Partnership to Deliver Stem Cell Therapies Under New Florida Law
Celularity Inc. has entered into a strategic partnership with Fountain Life to supply stem cell therapy products under Florida's new law, effective July 1, 2025, which allows licensed physicians to administer stem cell therapies for orthopedic, wound care, and pain management conditions without FDA IND approval. Fountain Life operates four longevity centers in the U.S., including two in Florida, and plans to deploy Celularity’s placenta-derived s...
07-09 12:30
Celularity Hails New Florida Law Opening Patient Access to Stem Cell Therapies
A new Florida law effective July 1 allows physicians to offer investigational stem cell therapies for orthopedics, wound care, and pain management under strict patient safety and ethical standards. Celularity Inc., a leader in ethically sourced stem cell therapies, commends the legislation and is prepared to supply the necessary stem cells, manufactured in FDA-registered facilities. The law requires informed consent and limits stem cell sources t...
07-01 12:30
CELU announces CFO termination; appoints interim incharge
Celularity (NASDAQ:CELU) terminated the employment of its chief financial officer, David Beers, effective immediately. Beers was terminated “without cause” under the terms of his employment agreement....
06-11 04:21
Celularity Announces Chief Financial Officer Transition
Celularity terminated its CFO, David Beers, effective immediately, without cause, and he will receive payments and benefits per his employment agreement. Joseph DosSantos, Senior Vice President of Finance, has been appointed interim CFO. The company also retained CFO Squad to provide financial and consulting services during the transition. 字符数: 164
06-10 20:15
Celularity Highlights Unique Potential Of Proprietary Advanced Biomaterial Technology As Novel Cellular Delivery System For Ocular Surface Reconstruction
Highlights the unique potential of Celularity's proprietary advanced biomaterial technology as a novel cellular delivery system for ocular surface reconstructionSupports broad range of regenerative medicine applications
06-02 20:04
Celularity Announces Publication Advancing Ocular Surface Reconstruction with Tri-Layer Amniotic Membrane Technology
Celularity的研究发表在《Regenerative Engineering and Translational Medicine》期刊，展示了其专有的三层脱细胞脱水人羊膜（DDHAM-3L）作为创新载体的潜力，支持iPSC来源的角膜缘干细胞（LSCs）增殖和干细胞特性，为角膜表面修复提供解决方案，并支持更广泛的再生医学应用。
06-02 12:00
Celularity Receives Nasdaq Notice Regarding Form 10-Q
Celularity Inc. (Nasdaq: CELU) was notified by Nasdaq on May 28, 2025, that it failed to timely file its Form 10-Q for the period ended March 31, 2025, violating Listing Rule 5250(c)(1). Nasdaq granted the company 60 days to submit a compliance plan, with a potential exception until November 17, 2025. Celularity is working to complete the filing and anticipates resuming compliance.
05-30 21:30
